Key result
Cannabis exposure was associated with a significantly lower rate of grade 2-3 oxaliplatin-induced peripheral neuropathy compared to controls (15.3% vs 27.9%).
Why the study?
Chemotherapy-induced peripheral neuropathy is a common dose-limiting oxaliplatin toxicity lacking effective prevention or treatment, though cannabis has suggested therapeutic and protective roles.
Does cannabis reduce oxaliplatin-induced peripheral neuropathy in oncology patients?
Cohort (n=513)
No
Does cannabis reduce oxaliplatin-induced peripheral neuropathy in oncology patients?
Absolute Event Rate: 15.3% vs 27.9%
p-value: p=<0.001
Cannabis use, particularly when initiated prior to chemotherapy, is associated with a reduced incidence of severe oxaliplatin-induced peripheral neuropathy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for cannabis in oxaliplatin neuropathy prevention; randomized trials needed before clinical adoption.
Waissengrin et al. (2021) conducted a cohort in Gastrointestinal malignancies (n=513). Cannabis vs. No cannabis exposure was evaluated on Chemotherapy-induced peripheral neuropathy (CIPN) grade 2-3 (p=<0.001). Cannabis exposure was associated with a significantly lower rate of grade 2-3 oxaliplatin-induced peripheral neuropathy compared to controls (15.3% vs 27.9%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: